Edotecarin: A novel topoisomerase I inhibitor

M. Wasif Saif, Robert B. Diasio

Research output: Contribution to journalReview article

25 Scopus citations

Abstract

Edotecarin (PHA-782615; formerly J-107088) is a derivative of NB-506, an indolocarbazole antitumor agent. It is a novel inhibitor of topoisomerase I that induces single-strand DNA cleavage more effectively than NB-506 or camptothecin (CPT) and at different DNA sequences. The DNA-topoisomerase I complexes induced by edotecarin are more stable than those occurring after exposure to CPT or NB-506. The antitumor activity of edotecarin is less cell cycle dependent than other topoisomerase I inhibitors. Being an indolocarbazole, it is structurally related to staurosporine but does not possess protein kinase inhibitory properties. In addition, edotecarin does not form active metabolites and is not a substrate for in vitro P450-mediated metabolism. The antitumor activity of edotecarin has been tested in vitro and in vivo, and inhibition of tumor growth has been observed in breast, cervix, pharynx, lung, prostate, colon, gastric, and hepatic cancer models. Edotecarin is effective on cells that have acquired resistance related to P-glycoprotein. In vitro synergy has been demonstrated when edotecarin was tested in combination with cisplatin, 5-fluorouracil etoposide, paclitaxel, doxorubicin, vincristine, CPT, and gemcitabine. Three phase 1 and 5 phase II studies have been carried out to date. Combination studies of edotecarin with other chemotherapeutic agents are in current clinical trials. The primary dose-limiting toxicities were grade 3/4 neutropenia and febrile neutropenia. Dose-limiting diarrhea was observed only with a twice-weekly administration schedule. Recent progress in preclinical and clinical studies of edotecarin is reviewed.

Original languageEnglish (US)
Pages (from-to)27-36
Number of pages10
JournalClinical colorectal cancer
Volume5
Issue number1
DOIs
StatePublished - May 2005

Keywords

  • Camptothecin
  • Pharmacogenetics
  • Pharmacokinetics
  • Phase II trials

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Edotecarin: A novel topoisomerase I inhibitor'. Together they form a unique fingerprint.

  • Cite this